COMMUNIQUÉS West-GlobeNewswire

Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET
05/11/2018
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal [...]
Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018
05/11/2018
BRIDGEWATER, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release [...]
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
05/11/2018
CAMBRIDGE, Mass. and BEIJING, China, Nov. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
05/11/2018
NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16
05/11/2018
BOSTON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat [...]
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
05/11/2018
CALGARY, Alberta and SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced [...]
Breathtec Provides Update on FAIMS Breathalyzer Development Program
05/11/2018
University of Florida to Complete Prototype Development VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: BTHCF ) (the “Company”) [...]
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
05/11/2018
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (Nasdaq: ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases [...]
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
05/11/2018
U.S. Galafold ® (Migalastat) Fabry Launch Tracking Significantly Ahead of Expectations- 100+ Patients Prescribed Galafold Since August Launch 3Q18 Global Galafold Net Product Sales of $20.6M Driven by Continued [...]
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
05/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual Scientific Meeting of the [...]
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12
05/11/2018
REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and [...]
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
05/11/2018
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10 million paid upon [...]
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company, will officially cut the ribbon on its San Diego based research and development facility on Monday [...]
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
05/11/2018
DURHAM, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a [...]
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
05/11/2018
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data - ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE [...]
AnaptysBio to Participate in Upcoming Investor Conferences
05/11/2018
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, [...]
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
05/11/2018
BURLINGTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the Centers for Medicare and Medicaid Services (CMS) has issued a product-specific J code for ZILRETTA ( [...]
Alpha Pro Tech, Ltd. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2018
05/11/2018
Revenue for the third quarter of 2018 increased modestly to $12.1 million, compared to $12.0 million for the third quarter of 2017. Revenue for the nine months ended September 30, 2018 increased 4.6% to $35.7 million, [...]
Invitation to investor meeting on November 8, 2018
05/11/2018
In connection with the release of BioPorto’s interim report covering the first nine months of 2018, BioPorto will hold an investor meeting on November 8, 2018 at. 3 pm. at BioPorto’s address Tuborg Havnevej 15, st., [...]

Pages